XOMA Royalty Corp. Files 8-K on Asset Acquisition/Disposition
Ticker: XOMAP · Form: 8-K · Filed: Nov 21, 2025 · CIK: 791908
| Field | Detail |
|---|---|
| Company | Xoma Royalty Corp (XOMAP) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0075, $0.05, $1.04 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, disposition, corporate-action
TL;DR
XOMA Royalty Corp. filed an 8-K on 11/21/25 for asset acquisition/disposition.
AI Summary
On November 21, 2025, XOMA Royalty Corp. filed an 8-K report detailing the completion of an acquisition or disposition of assets. The filing also includes information on other events and financial statements and exhibits. XOMA Royalty Corp. is incorporated in Nevada and its fiscal year ends on December 31.
Why It Matters
This 8-K filing indicates a significant corporate action by XOMA Royalty Corp., potentially impacting its asset base and future financial performance.
Risk Assessment
Risk Level: medium — Filings related to asset acquisitions or dispositions can introduce new risks or alter existing ones for a company.
Key Players & Entities
- XOMA Royalty Corp. (company) — Filer of the 8-K report
- November 21, 2025 (date) — Date of the earliest event reported
- Nevada (location) — State of incorporation
- December 31 (date) — Fiscal year end
FAQ
What specific assets were acquired or disposed of by XOMA Royalty Corp. on or before November 21, 2025?
The filing indicates the completion of an acquisition or disposition of assets, but the specific details of these assets are not provided in the provided text.
What is the nature of the 'Other Events' mentioned in the 8-K filing?
The filing lists 'Other Events' as an item information category, but the specific nature of these events is not detailed in the provided text.
What financial statements and exhibits are included with this 8-K filing?
The filing states that 'Financial Statements and Exhibits' are included, but the content of these exhibits is not specified in the provided text.
What was XOMA Royalty Corp.'s previous company name and when did the name change occur?
The filing lists former company names including 'XOMA Corp' with a name change date of 20120119, 'XOMA LTD /DE/' with a name change date of 19990107, and 'XOMA CORP /DE/' with a name change date of 19920703.
What is XOMA Royalty Corp.'s SIC code and what industry does it belong to?
XOMA Royalty Corp.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,157 words · 5 min read · ~4 pages · Grade level 11.1 · Accepted 2025-11-21 08:03:29
Key Financial Figures
- $0.0075 — ange on which registered Common Stock, $0.0075 par value XOMA The Nasdaq Global Ma
- $0.05 — ve Perpetual Preferred Stock, par value $0.05 per share XOMAP The Nasdaq Global M
- $1.04 — Shares ") for a price per Share of (i) $1.04 (the " Cash Amount "), payable subject
Filing Documents
- d65279d8k.htm (8-K) — 36KB
- 0001193125-25-290638.txt ( ) — 196KB
- xoma-20251121.xsd (EX-101.SCH) — 4KB
- xoma-20251121_def.xml (EX-101.DEF) — 14KB
- xoma-20251121_lab.xml (EX-101.LAB) — 24KB
- xoma-20251121_pre.xml (EX-101.PRE) — 15KB
- d65279d8k_htm.xml (XML) — 8KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (a) Financial Statements of Business Acquired. The financial statements of LAVA and related notes as of and for the years ended December 31, 2024 and 2023 and the unaudited financial statements of LAVA as of September 30, 2025 and 2024 and for the periods then ended and related notes will be included in an exhibit that will be filed in an amendment to this Current Report on Form 8-K within the period specified in Item 9.01(a)(3) of Form 8-K. (b) Pro Forma Financial Information. The unaudited pro forma condensed combined financial information of XOMA and LAVA as of and for the nine months ended September 30, 2025 and the year ended December 31, 2024 and the related notes will be included in an exhibit that will be filed in an amendment to this Current Report on Form 8-K within the period specified in Item 9.01(a)(3) of Form 8-K. (d)Exhibits. Exhibit No. Description 2.1 Share Purchase Agreement, by and among XOMA Royalty Corporation and LAVA Therapeutics N.V., dated August 3, 2025 (incorporated by reference to Exhibit 2.1 to LAVA's Current Report on Form 8-K filed with the SEC on August 4, 2025). 2.2 Amendment to Share Purchase Agreement, by and among XOMA Royalty Corporation and LAVA Therapeutics N.V., dated October 17, 2025 (incorporated by reference to Exhibit 2.1 to LAVA's Current Report on Form 8-K filed with the SEC on October 17, 2025). 2.3 Form of Contingent Value Rights Agreement (incorporated herein by reference to Exhibit C of Exhibit 2.1 to LAVA's Current Report on Form 8-K filed with the SEC on October 17, 2025). 99.1 Press Release issued by XOMA Royalty Corporation on November 21, 2025 (incorporated herein by reference to Exhibit (a)(5)(D) to the Schedule TO-T/A filed by XOMA Royalty Corporation on November 21, 2025). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XOMA ROYALTY CORPORATION Date: November 21, 2025 By: /s/ Owen Hughes Name: Owen Hughes Title: Chief Executive Officer